Cargando…
Improved anti-fibrotic effects by combined treatments of simvastatin and NS-398 in experimental liver fibrosis models
BACKGROUND/AIMS: Efficient anti-fibrotic therapies are required for the treatment of liver cirrhosis. Hydroxymethylglutaryl-coenzyme A reductase inhibitors (statins) and cyclooxygenase-2 (COX-2) inhibitors have been reported to have anti-fibrotic effects. Here, we investigated whether combined treat...
Autores principales: | Kang, Seong Hee, Yim, Hyung Joon, Hwang, Ji-won, Kim, Mi-jung, Lee, Young-Sun, Jung, Young Kul, Yim, Hyungshin, Kim, Baek-Hui, Park, Hae-Chul, Seo, Yeon Seok, Kim, Ji Hoon, Yeon, Jong Eun, Um, Soon Ho, Byun, Kwan Soo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Association of Internal Medicine
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9271712/ https://www.ncbi.nlm.nih.gov/pubmed/35811365 http://dx.doi.org/10.3904/kjim.2021.138 |
Ejemplares similares
-
Exosomes derived from palmitic acid-treated hepatocytes induce fibrotic activation of hepatic stellate cells
por: Lee, Young-Sun, et al.
Publicado: (2017) -
Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression
por: Gim, Jeong-An, et al.
Publicado: (2021) -
Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis
por: Ahn, Young Eun, et al.
Publicado: (2021) -
Direct Bilirubin Is More Valuable than Total Bilirubin for Predicting Prognosis in Patients with Liver Cirrhosis
por: Lee, Han Ah, et al.
Publicado: (2021) -
Circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease
por: Kim, Tae Hyung, et al.
Publicado: (2021)